1. Lumvoa won total approval for both active and chronic Thyroid Eye Disease.
2. Cuts Tepezza treatment in half
3. phase three trials demolished placebo
4. $1.1b liquid for launch
5. Pricing target estimate $35
1. Lumvoa won total approval for both active and chronic Thyroid Eye Disease.
2. Cuts Tepezza treatment in half
3. phase three trials demolished placebo
4. $1.1b liquid for launch
5. Pricing target estimate $35